Cargando…

Evaluation of a primary care-based opioid and pain review service: a mixed-methods evaluation in two GP practices in England

BACKGROUND: Opioid prescribing to treat chronic non-cancer pain has rapidly increased, despite a lack of evidence for long-term safety and effectiveness. A pain review service was developed to work with patients taking opioids long-term to explore opioid use, encourage non-drug-based alternatives, a...

Descripción completa

Detalles Bibliográficos
Autores principales: Scott, Lauren J, Kesten, Joanna M, Bache, Kevin, Hickman, Matthew, Campbell, Rona, Pickering, Anthony E, Redwood, Sabi, Thomas, Kyla
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Royal College of General Practitioners 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6890470/
https://www.ncbi.nlm.nih.gov/pubmed/31791939
http://dx.doi.org/10.3399/bjgp19X707237
Descripción
Sumario:BACKGROUND: Opioid prescribing to treat chronic non-cancer pain has rapidly increased, despite a lack of evidence for long-term safety and effectiveness. A pain review service was developed to work with patients taking opioids long-term to explore opioid use, encourage non-drug-based alternatives, and, where appropriate, support dose reduction. AIM: To evaluate the service and its potential impact on opioid use, health and wellbeing outcomes, and quality of life (QoL). DESIGN AND SETTING: Mixed-methods evaluation of a one-to-one service based in two GP practices in South Gloucestershire, England, which took place from September 2016 to December 2017. METHOD: Quantitative data were collected on baseline demographics; data on opioid use, misuse, and dose, health, wellbeing, QoL, and pain and interference with life measures were collected at baseline and follow-up. Twenty-five semi-structured interviews (n = 18 service users, n = 7 service providers) explored experiences of the service including perceived impacts and benefits. RESULTS: Of 59 patients who were invited, 34 (57.6%) enrolled in the service. The median prescribed opioid dose reduced from 90 mg (average daily morphine equivalent; interquartile range [IQR] 60 to 240) at baseline to 72 mg (IQR 30 to 160) at follow-up (P<0.001); three service users stopped using opioids altogether. On average, service users showed improvement on most health, wellbeing, and QoL outcomes. Perceived benefits were related to wellbeing, for example, improved confidence and self-esteem, use of pain management strategies, changes in medication use, and reductions in dose. CONCLUSION: The service was well received, and health and wellbeing outcomes suggest a potential benefit. Following further service development, a randomised controlled trial to test this type of care pathway is warranted.